Compare PTCT & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | GTLB |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | 991 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.5B |
| IPO Year | 2006 | 2021 |
| Metric | PTCT | GTLB |
|---|---|---|
| Price | $63.29 | $47.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 27 |
| Target Price | ★ $80.65 | $37.17 |
| AVG Volume (30 Days) | 918.2K | ★ 5.3M |
| Earning Date | 05-07-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | $264,734,000.00 | ★ $955,224,000.00 |
| Revenue This Year | N/A | $18.72 |
| Revenue Next Year | $17.70 | $16.05 |
| P/E Ratio | $69.20 | ★ N/A |
| Revenue Growth | ★ 36.19 | 25.81 |
| 52 Week Low | $58.90 | $18.73 |
| 52 Week High | $90.87 | $55.55 |
| Indicator | PTCT | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 56.12 |
| Support Level | N/A | $46.01 |
| Resistance Level | $68.93 | $50.67 |
| Average True Range (ATR) | 1.97 | 1.69 |
| MACD | -0.32 | -0.46 |
| Stochastic Oscillator | 22.43 | 40.88 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.